CANCERS TREATED WITH
CAR-T THERAPY
Which cancers qualify for CAR-T today, which are in clinical trials, and how to determine whether your specific cancer subtype matches an available product.
analyticsAt a Glance
- check_circleCAR-T is approved for ALL, DLBCL, follicular lymphoma, mantle cell lymphoma, and myeloma
- check_circleExpanding to solid tumours โ trials in lung, liver, gastric, and cervical cancers are active
- check_circleChina has NMPA-approved CAR-T products for blood cancers at 40โ70% lower cost than the US
- check_circleEligibility depends on prior treatment history, performance status, and target antigen expression
Specificity Is the Mechanism
Every CAR-T product targets one specific protein. If your cancer expresses that protein, you may be eligible. If it doesn't, that product has nothing to work with. This specificity is what makes CAR-T precise โ and what limits its current reach.
โFor some patients, the answer is a clear yes. For others, it's not yet yes โ but may become one as approvals expand.โ
Currently Approved Cancer Types
B-Cell Lymphomas
DLBCL, primary mediastinal LBCL, high-grade B-cell lymphoma, follicular lymphoma, mantle cell lymphoma. The most established CAR-T territory.
B-Cell ALL
Relapsed/refractory B-ALL in patients up to 25 (Kymriah) and adults (Breyanzi). CR rates 70-90% โ striking for an exhausted population.
Multiple Myeloma
Relapsed/refractory after multiple prior lines. Two BCMA-targeting products: Abecma (73% ORR) and Carvykti (97.9% ORR).
Cancers in Active Clinical Trials
No approval yet, but active investigation across multiple cancer types.
| Cancer Type | Key Challenge | Trial Status |
|---|---|---|
| Acute Myeloid Leukemia (AML) | Target proteins overlap with normal marrow | Multiple Phase I/II trials |
| Chronic Lymphocytic Leukemia (CLL) | T-cell dysfunction in CLL patients | Liso-cel FDA-approved 2024 |
| T-Cell Lymphomas | Target overlaps with therapy's own cells | Modified approaches in early trials |
| Solid Tumours (lung, breast, pancreatic) | TME suppression, antigen heterogeneity | Phase I/II; modest early results |
| Glioblastoma | Blood-brain barrier penetration | Intracranial delivery showing promise |
Frequently Asked Questions
About CAR-T Cancer Types
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Know If a CAR-T Product Matches Your Cancer?
Upload your reports and our team will assess which product โ if any โ matches your cancer subtype and treatment history.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.